LIVZON PHARMA (01513) released its performance for the first three quarters, with a net profit attributable to shareholders of 1.754 billion yuan, a year-on-year increase of 4.86%.
Lizhu Pharmaceuticals (01513) releases its performance report for the first three quarters of 2025, with the group achieving a revenue of 9.116 billion yuan.
LIVZON PHARMA (01513) released its performance for the first three quarters of 2025, with the group achieving operating income of 9.116 billion yuan, a year-on-year increase of 0.38%; net profit attributable to company shareholders was 1.754 billion yuan, a year-on-year increase of 4.86%; basic earnings per share were 1.96 yuan.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
